OneCell Diagnostics’ Mohan Uttarwar Discusses How AI Helps To Predict Cancer’s Next Move

Company Co-Founder Shares How Decoding Cancer At Single Cell Level Could Take Guesswork Out Of Recurrence With AI-Powered Diagnostics

Part 1 of 2: In an interview with Medtech Insight, Uttarwar breaks down how OneCell’s proprietary single cell biopsy platform is rewriting the rules of cancer diagnostics – not just identifying cancer at the cellular level but predicting its potential return with unprecedented accuracy. He also shares how the company’s approach leverages single cell biopsy technology and machine learning to spot signs of cancer’s return before it manifests clinically.

In an interview with Medtech Insight, Uttarwar breaks down how OneCell’s proprietary single-cell biopsy platform is rewriting the rules of cancer diagnostics
Key Takeaways

· OneCell's platform isolates and analyzes individual circulating tumor cells (CTCs) to provide a more granular and dynamic view of a patient's disease state.

· By training proprietary machine learning models on complex cell-level data, OneCell can assess recurrence risk — offering oncologists a powerful predictive tool for treatment planning.

· With early validation in motion and plans for wider clinical deployment, the company is focused on translating its technology into real-world oncology workflows.

In a world where cancer remains one of the most complex and relentless diseases, OneCell Diagnostics, an artificial intelligence-powered cancer...

Welcome to Medtech Insight

Create an account to read this article

More from Interviews

Bivacor Rotary Heart Could Upend The Artificial Heart Market, If It Reaches Its Destination

 
• By 

Bivacor aims to be first to the US market with a permanent total artificial heart, starting with use as a bridge to transplant. CMO William Cohn says data from countries with low transplant rates could support pivotal trials and long-term use.

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

From Imitation To Action: Johns Hopkins Robot Autonomously Performs Key Step In Gallbladder Surgery

 
• By 

Researchers at Johns Hopkins have used a robotic system to autonomously perform a key part of gallbladder surgery without a surgeon's hand. Lead author Axel Krieger says it could take five to 10 years before an autonomous robotic system will reach human trials and expects regulatory hurdles.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By 

Joshi joins the parent company of Citeline, home of Medtech Insight, to focus on AI, business harmonization and long-term growth.

More from Medtech Insight

Ochsner Surgeon In ‘The Big Easy’ Eases Patient’s Pain With Skill And Virtual Reality

 

A surgeon at Ochsner Health in New Orleans was able to successfully remove a rare and dangerous tumor from a patient’s spine using cutting-edge technology that would have otherwise made the procedure too risky.

Execs On The Move: June 30–July 4, 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

FDA Commissioner’s Voucher Program Should Include Devices, Transplant Technology Firm Says

 
• By 

The FDA's new Commissioner’s National Priority Voucher program aims to expedite drug approvals significantly. Device firms like XVIVO advocate for a similar initiative for devices, emphasizing the potential for faster reviews and improved patient access to lifesaving technologies.